Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 1, 2008, Pages 42-45

  Uygun, Ahmet ^a   Ozel, A Melih ^b   Yildiz, Oguzhan ^a   Aslan, Murat ^a   Yesilova, Zeki ^a   Erdil, Ahmet ^a   Bagci, Sait ^a   Gunhan, Omer ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

Eradication; Helicobacter pylori; Second line therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DYSPEPSIA; FECES COLOR; FEMALE; HEADACHE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TURKEY (REPUBLIC); VOMITING;

EID: 37249061706     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04984.x     Document Type: Article

References (18)

1. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N. Engl. J. Med. 1995 333 : 984 91.
2. The European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastrich Consensus Report. Gut 1997 41 : 8 13.
3. de Boer WA, Tytgat GN. Regular review: treatment of Helicobacter pylori infection. Br. Med. J. 2000 320 : 31 4.
4. Baòos F, Madridejos R, Cabezas C, Burrull M, Lafuente C, Morera R. Effectiveness of omeprazole, clarithromycin and amoxicillin therapy to eradicate Helicobacter pylori in patients with active peptic ulcer. Preliminary results GENPY study. Med. Clin. (Barc). 2000 114 : 441 3.
5. Palmas F, Pellicano R, Massimetti E, Berruti M, Fagoone S, Rizzetto M. Eradication of Helicobacter pylori infection with proton pump inhibitor-based triple therapy. A randomized study. Panminerva Med. 2002 44 : 145 7.
6. Uygun A, Yeşilova Z, Ateş Y et al. Comparison of 7 and 14 days lansoprazole, amoxicillin, clarithromycin therapies to eradicate HP in HP positive non-ulcer dyspeptic patients in Turkish population [Abstract]. Turkish J Gastroenterol. 2004 (Suppl. 1 138.
7. Cuchi E, Forné M, Quintana S, Lite J, Garau J. Evolución de la sensibilidad de 235 cepas de Helicobacter pylori entre 1995 y 1998 e impactpo del tratamiento antibiótico. Enf. Infect. Microbiol. Clin. 2002 20 : 157 60.
8. Aydin A, Faik G, Önder F, Akarca US, Tunçyürek M, Musaoǧlu A. The effectiveness of Ranitidine bismuth citrate- amoxicillin - clarithromycin combination in eradication of HP in clarithromycin-resistant and -sensitive cases [Abstract]. Turkish J Gastroenterol. 2004 (Suppl. 1 57.
9. Malfertheiner P, Megraud F, O'Morrain C et al. Current concepts in the management of Helicobacter pylori infection - the Maastrch 2-2000 Consensus report. Aliment. Pharmacol. Ther. 2002 16 : 167 80.
10. Gisbert JP, Pajares JM. Review article: Helicobacter pylori'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment. Pharmacol. Ther. 2002 16 : 1047 57.
11. Boixeda D, Bermejo F, Nartin-De-Argila C et al. Efficacy of quadruple therapy with pantaprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2002 16 : 1457 60.
12. Gasbarrini A, Ojetti V, Armuzzi A et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 2000 14 : 79 83.
13. Calvet X, Montserrat A, Güell M, Vergara M, Gené E. Ranitidine-bismuth citrate, tetracycline and metaronidasole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study. Eur. J. Gastroenterol. Hepatol. 2004 16 : 987 90.
14. Matsuhisa T, Kawai T, Masaoka T et al. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori infection in the Japanese population: a multicenter study in the Tokyo Metropolitan area. Helicobacter. 2006 11 : 152 8.
15. Masaoka T, Suzuki H, Kurabayashi K, Kamiya AG, Ishii H. Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. Aliment. Pharmacol. Ther. 2004 20 (Suppl. 1 68 73.
16. Masaoka T, Suzuki H, Kurabayashi K et al. Could frameshift mutations in the frxA and rdxA genes of Helicobacter pylori be a marker for metronidazole resistance? Aliment. Pharmacol. Ther. Symp. Ser. 2006 2 : 81 7.
17. Goodwin A, Kersulyte D, Sisson G, Veldhuyzen van Zanten SJ, Berg DE, Hoffman PS. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol. Microbiol. 1998 28 : 383 93.
18. Jenks PJ, Ferrero RL, Labigne A. The role of the rdxA gene in the evolution of metronidazole resistance in Helicobacter pylori. J. Antimicrob. Chemother. 1999 43 : 753 8.